Preclinical Toxicological Study of Release-Active Preparations for Prediction of Their Pharmacological Activity and Side Effects
- Authors: Zhavbert E.S.1, Surkova E.I.1, Yakovleva N.N.1, Dugina Y.L.1, Epshtein O.I.1, Bugaeva L.I.2, Lebedeva S.A.2, Petrov V.I.2
- 
							Affiliations: 
							- Materia Medica Holding
- Volgograd State Medical University, Ministry of Health of the Russian Federation
 
- Issue: Vol 161, No 2 (2016)
- Pages: 252-256
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/237308
- DOI: https://doi.org/10.1007/s10517-016-3389-z
- ID: 237308
Cite item
Abstract
We studied chronic toxicity of a few release-active preparations: Dietressa (release-active preparation of affinity-purified antibodies to type 1 cannabinoid receptor), Divasa (releaseactive preparation containing a combination of affinity-purified antibodies to brain-specific S-100 protein and endothelial NO-synthase), Cardostin (release-active preparation containing a combination of affinity-purified antibodies to C-terminal fragment of angiotensin II type 1 receptor and endothelial NO-synthase), and Bation (release-active preparation containing a combination of affinity-purified antibodies to IFN-γ and CD4). We evaluated not only side and toxic effects, but also the relationships between these effects and pharmacological activities of the preparations. The data of preclinical toxicological studies of the release-active preparations can be used for prediction of their pharmacological activity.
About the authors
E. S. Zhavbert
Materia Medica Holding
							Author for correspondence.
							Email: zhavbertes@materiamedica.ru
				                					                																			                												                	Russian Federation, 							Moscow						
E. I. Surkova
Materia Medica Holding
														Email: zhavbertes@materiamedica.ru
				                					                																			                												                	Russian Federation, 							Moscow						
N. N. Yakovleva
Materia Medica Holding
														Email: zhavbertes@materiamedica.ru
				                					                																			                												                	Russian Federation, 							Moscow						
Yu. L. Dugina
Materia Medica Holding
														Email: zhavbertes@materiamedica.ru
				                					                																			                												                	Russian Federation, 							Moscow						
O. I. Epshtein
Materia Medica Holding
														Email: zhavbertes@materiamedica.ru
				                					                																			                												                	Russian Federation, 							Moscow						
L. I. Bugaeva
Volgograd State Medical University, Ministry of Health of the Russian Federation
														Email: zhavbertes@materiamedica.ru
				                					                																			                												                	Russian Federation, 							Volgograd						
S. A. Lebedeva
Volgograd State Medical University, Ministry of Health of the Russian Federation
														Email: zhavbertes@materiamedica.ru
				                					                																			                												                	Russian Federation, 							Volgograd						
V. I. Petrov
Volgograd State Medical University, Ministry of Health of the Russian Federation
														Email: zhavbertes@materiamedica.ru
				                					                																			                												                	Russian Federation, 							Volgograd						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					